TREK-1 Antagonist Novel Antidepressant Mechanism Naturally Occurring · French Discovery

Spadin

TREK-1 Antagonist · Sortilin-Derived Peptide · mSP (Mini-Spadin)

"A naturally occurring peptide that blocks TREK-1 potassium channels — producing rapid antidepressant effects through a mechanism completely distinct from every approved antidepressant. TREK-1 overactivity is implicated in depression. Blocking it with spadin produces effects in mouse models comparable to fluoxetine but without the weeks-long delay. No human trials yet."

Origin
Sortilin propeptide · NTSR3 receptor
Target
TREK-1 (TWIK-related K⁺ channel 1) antagonist
Key finding
Fast antidepressant in mouse models · no obvious side effects
Human trials
None conducted
Endogenous
Naturally produced — sortilin processing
Origin & The TREK-1 Story

The potassium channel nobody thought about for depression

TREK-1 (TWIK-related K⁺ channel 1, encoded by KCNK2) is a two-pore domain potassium channel expressed throughout the brain, particularly in regions relevant to depression: the hippocampus, prefrontal cortex, and raphe nuclei. Mice genetically lacking TREK-1 are resistant to depression in multiple animal models — they don't show helplessness, anhedonia, or anxiety responses to stress that wild-type mice display. This established TREK-1 as a potential antidepressant target, but the concept of blocking a potassium channel to treat depression was pharmacologically unconventional.

Spadin was discovered by Michel Lazdunski's group at the Institut de Pharmacologie Moléculaire et Cellulaire in Nice. They identified that sortilin — a multi-ligand sorting receptor — is processed to release a propeptide that naturally inhibits TREK-1 channels. This propeptide, named spadin, was then characterised as a novel endogenous antidepressant peptide. The peptide is produced when sortilin undergoes proteolytic processing in the trans-Golgi network — spadin is released and acts on TREK-1 channels in a paracrine and potentially endocrine fashion.

In rodent depression models (forced swim, tail suspension, chronic mild stress), spadin produced antidepressant effects within days — comparable to or faster than fluoxetine (which requires 2–3 weeks in mice). Unlike ketamine, spadin produced no locomotor changes, no dissociation, and no obvious off-target effects in the animal studies. A truncated version, mini-spadin (mSP), retains full TREK-1 blocking activity with improved pharmacokinetics.

Why TREK-1 matters: TREK-1 is a "leak" potassium channel — it maintains neuronal excitability close to the resting membrane potential. In the raphe nuclei, TREK-1 regulates serotonin neuron firing rate. TREK-1 overactivity hyperpolarises serotonergic neurons, reducing their firing and serotonin release — the same deficit that SSRIs try to correct by blocking serotonin reuptake. Spadin corrects the upstream problem rather than compensating downstream.

Mechanism

TREK-1 blockade — the upstream serotonin solution

How Spadin Works

1
TREK-1 K⁺ channel antagonism: Spadin binds the extracellular domain of TREK-1, blocking potassium efflux through the channel. This reduces hyperpolarisation of serotonergic neurons in the raphe nuclei — effectively disinhibiting them and allowing normal firing rates to be restored.
2
Serotonin neuron disinhibition: With TREK-1 blocked, raphe serotonergic neurons fire at normal-to-higher rates, increasing 5-HT release in projection areas including the prefrontal cortex, hippocampus, and amygdala. This is the same downstream result as SSRIs but achieved through a fundamentally different mechanism — upstream disinhibition rather than downstream reuptake blockade.
3
Speed advantage over SSRIs: SSRIs require weeks because they initially cause autoreceptor desensitisation that partially offsets their effect — the 5-HT₁A autoreceptors must desensitise before full antidepressant effect emerges. Spadin's mechanism bypasses this delay by directly restoring serotonergic tone without autoreceptor complications.
4
BDNF upregulation: Like all effective antidepressants, spadin ultimately increases hippocampal BDNF — the neurotrophin critical for neurogenesis and synaptic plasticity. This effect was confirmed in the rodent studies and provides a mechanistic link to the longer-term structural plasticity changes that underlie sustained antidepressant benefit.
Community Use — Very Limited

Where things stand

Community use of spadin is currently extremely limited — less than virtually any other compound in this book. The barriers: the science is recent (primary publications 2012–2023), synthesis and sourcing of verified spadin from research chemical suppliers is difficult, the intranasal delivery route for brain access hasn't been characterised, and the mechanism (TREK-1 channel pharmacology) is less intuitive than the BDNF or GLP-1 mechanisms that attract community attention.

Mini-spadin (mSP) has been shown to have improved stability over the full-length spadin while retaining TREK-1 blocking activity — and is the more pharmacologically attractive development candidate. If any human trials develop, they will likely use mSP rather than the full parent peptide.

⚡ What to Watch

Publications from Lazdunski and collaborating groups on spadin/mSP pharmacokinetics and in vivo optimisation. Any announcement of Phase 1 human trials — this would be the signal that the compound has cleared preclinical safety hurdles. The broader TREK-1 pharmacology field is attracting pharmaceutical interest as a depression target — any corporate TREK-1 antagonist programme that reaches clinical trials validates the target even if using a different molecule. Watch for TREK-1 in mental health pharma pipeline announcements.

Honest Assessment

Editor's summary

Spadin is the most mechanistically novel antidepressant candidate in this book — a naturally occurring peptide that antagonises a potassium channel to restore serotonergic neuron firing, producing fast antidepressant effects through a pathway completely orthogonal to everything currently approved. The TREK-1 knockout mouse data establishing the target's relevance to depression is solid basic science. The spadin animal data is promising. The human data is non-existent.

What makes spadin particularly interesting is that it is endogenous — your body produces it through sortilin processing. Like LL-37 in the immune space, spadin represents a natural regulatory mechanism that may be deficient in some depressed individuals — with potential for replacement therapy rather than pharmacological manipulation of foreign targets.

Verdict
"The most novel antidepressant mechanism in peptide science — TREK-1 potassium channel antagonism producing fast serotonin neuron disinhibition. An endogenous peptide with a compelling animal data set. No human trials. The TREK-1 target is scientifically well-validated; whether spadin or mSP becomes the vehicle for human translation remains to be seen."